Sick of corporate greed

The scandal of expensive medicines

In spite of advances in medical innovation, millions of people around the world suffer and die from treatable conditions because medicines are too expensive.
 
Historically this has tragically affected low and middle-income countries. But in recent years, the NHS has also struggled to pay extortionate prices and has had to turn down or ration new medicines. 
 

Corporate profits trump public health

Why are medicines so expensive? Drug companies can charge runaway prices because new drugs are protected by legal monopolies. This profit-driven model has made the pharmaceutical industry the most profitable in the world. Drug companies justify high prices by claiming they need to recoup their research and development costs. But nine of the top ten pharmaceutical companies spend more on marketing than on research and development. Also, most early-stage innovative research is publically funded. Drug companies often buy up taxpayer funded research and reap the profits from charging extortionate prices while patients are denied access to vital medicines.

Join the fight for affordable medicines

We’ve joined forces with Missing Medicines – a coalition of UK organisations fighting for affordable medicines globally. We want conditions on all public health research to make sure the medicines developed are affordable and accessible here in the UK and across the world.

Latest Blog Posts

The UK government has blatantly chosen to side with big pharma over patients


28 May 2019

The UK government has recklessly blocked global efforts to tackle big pharma secrecy this week in Geneva. But across the world, people are mobilising to give a strong message that it’s time governments put people over the power of big pharma. 

Why is the UK trying to delete all mentions of high drug prices at the World Health Assembly?


21 May 2019

This week in Geneva a resolution is being voted on which could help make drugs more affordable around the world. 

It's time to get privatised medicines out of our public health system


03 December 2018

It’s good news for the NHS and patients. After years of big pharma having patent control over a medicine and hiking up its price extortionately, a drug that treats rheumatoid arthritis and Crohn's disease, adalimumab, is being replaced with much cheaper alternatives.